FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

SCA Pharmaceuticals FentaNYL 500 mcg/250 mL Recall

FentaNYL 500 mcg/250 mL - Bupivacaine HCl 0

SCA Pharmaceuticals · Windsor, CT

Risk level
Class II
Reported by FDA
Aug 2, 2023
Recall ID
D-0945-2023
Check your lot numberHow we source this data

Summary

SCA Pharmaceuticals recalled FentaNYL 500 mcg/250 mL starting Jul 20, 2023. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0945-2023 on Aug 2, 2023. Reason: cGMP deviations: due to shipment of rejected units. Status: Terminated.

Why it was recalled

cGMP deviations: due to shipment of rejected units.

Product description

FentaNYL 500 mcg/250 mL - Bupivacaine HCl 0.1% in 0.9% Sodium Chloride 250mL Bag, Injection for Epidural Use (fentaNYL Concentration - 2 mcg/mL), Rx Only, Single Dose Container, SCA Pharmaceuticals, 755 Rainbow Rd, Windsor, CT 06095, NDC# 70004-0253-40

Lot numbers, UPCs & expiration codes

Lot # 1223047134, Use By: 09/21/2023

Where it was sold

KY and NJ

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0945-2023
Classification
Class II
Status
Terminated
Recall initiated
Jul 20, 2023
FDA report date
Aug 2, 2023
Quantity
183 bags
Recall type
Voluntary: Firm initiated
Recalling firm
SCA Pharmaceuticals

Original FDA data

Every field from FDA enforcement report D-0945-2023, exactly as published.

Show all FDA fields
City
Windsor
State
CT
Status
Terminated
Country
United States
Event ID
92737
Address
755 Rainbow Rd Ste B
Code information
Lot # 1223047134, Use By: 09/21/2023
Postal code
06095-1024
Report date
Aug 2, 2023
Product type
Drugs
Recall number
D-0945-2023
Classification
Class II
Recalling firm
SCA Pharmaceuticals
Product quantity
183 bags
Termination date
Sep 21, 2023
Reason for recall
cGMP deviations: due to shipment of rejected units.
Voluntary / mandated
Voluntary: Firm initiated
Product description
FentaNYL 500 mcg/250 mL - Bupivacaine HCl 0.1% in 0.9% Sodium Chloride 250mL Bag, Injection for Epidural Use (fentaNYL Concentration - 2 mcg/mL), Rx Only, Single Dose Container, SCA Pharmaceuticals, 755 Rainbow Rd, Windsor, CT 06095, NDC# 70004-0253-40
Distribution pattern
KY and NJ
Recall initiation date
Jul 20, 2023
Initial firm notification
Letter
Center classification date
Jul 26, 2023

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0945-2023, published Aug 2, 2023. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls